Atlas Trials

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Clinical trial NCT05522491 · NOT_YET_RECRUITING

Trial details

NCT number
NCT05522491
Sponsor
Hebei Medical University Fourth Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Solid Tumor
Start date
2026-09-01
Primary completion
2030-09-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.